Genotypes or phenotypes in cardiovascular diagnosis?

European Heart Journal

Volumn 27, Issue 18, 2006, Pages 2150-2151

  Damgaard, Dorte ^a   Faergeman, Ole ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ANALYSIS; GENOTYPE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SCREENING;

GENETIC SCREENING; GENETIC TESTING; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PHENOTYPE;

EID: 33748801497     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl172     Document Type: Editorial

References (11)

1. van Aalst-Cohen ES, Jansen ACM, Tanck MWT, Defesche JC, Trip MD, Lansberg PJ, Stalenhoef AFH, Kastelein JJP. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 2006;27:2240-2246. First published on July 6, 2006, doi:10.1093/eurheartj/ehl113.
2. Fouchier S, Kastelein JJ, Defesche J. Update of the molecular basis of familial hypercholesterolemia in the Netherlands. Hum Mutat 2005;26:550-556.
3. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-168.
4. Marks D, Thorogood M, Neil HA, Wonderling D, Humphries SE. Comparing costs and benefits over a 10-year period of strategies for familial hypercholesterolaemia screening. J Publ Health Med 2003;25:47-52.
5. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED. ACC/ESC Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus. Documents of the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-1991.
6. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974;249:5153-5162.
7. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987;84:6919-6923.
8. Pimstone SN, Sun XM, du SC, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998;18:309-315.
9. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-1023.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
11. Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, Jensen LG, Faergeman O. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005;180:155-60.